MWMotoshi Wada

Motoshi Wada

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Motoshi Wada has a total of 145 co-authors. Here are the top co-authors by number of shared publications:

  • Hironori Kudo

    Department of Pediatric Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan

    9 shared publications
  • Masatoshi Hashimoto

    Department of Pediatric Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan

    8 shared publications
  • Hideyuki Sasaki

    Department of Surgery, Miyagi Children's Hospital, Sendai, Japan

    7 shared publications
  • Ryo Ando

    Department of Pediatric Surgery, Tohoku University School of Medicine, Japan

    7 shared publications
  • Ryuji Okubo

    Department of Pediatric Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan

    7 shared publications
  • Megumi Nakamura

    Department of Pediatric Surgery, Tohoku University School of Medicine, Japan

    6 shared publications

Latest Publications

  • Open Access

    Nutritional intake and growth in children with intestinal failure: An exploratory cross-sectional study

    by Naoko Inamura, Miyuki Takeda, Manami Sasaki, Yumi Nishikawa, Chihiro Tanaka, Mikiko Fuda, Tsuyoshi Sakurai, Ryo Ando, Megumi Nakamura, Hironori Kudo, et al.

  • Open Access

    Proof of principle study for the development of the world’s smallest long-term short bowel syndrome pig model using microminipigs

    by Hironori Kudo, Ryoma Endo, Eiji Kobayashi, Yuto Yamazaki, Motoshi Wada

  • Open Access

    Necessity of enterostomy at the initial operation in neonatal intestinal perforation: A nationwide matched study in Japan

    by Tsuyoshi Sakurai, Hisateru Tachimori, Hiroaki Miyata, Hideyuki Sasaki, Motoshi Wada


  • Open Access

    Six-Month Safety and Effectiveness of Teduglutide in Patients with Short Bowel Syndrome in Japan: Interim Analysis of Post-marketing Surveillance

    by Motoshi Wada, Shiro Nakamura, Ayako Hayashi, Rie Otake, Masakazu Miyamoto, Tomoko Tanaka

    Introduction Patients with intestinal failure caused by short bowel syndrome (SBS) are dependent on parenteral support (PS) for nutrition. Teduglutide, an analogue of glucagon-like peptide 2, has been shown to decrease reliance on PS with an acceptable safety profile in multiregional phase 3 clinical trials, but currently there are no reports examining treatment outcomes with teduglutide in the real-world population in Japan. This interim analysis of a 36-month post-marketing surveillance (PMS) reports the safety and effectiveness of teduglutide in adults and pediatric patients with SBS in Japan. Methods This 6-month analysis was conducted as part of a prospective, all-case, 36-month PMS of teduglutide (Takeda Pharmaceutical Company Limited) conducted in patients with SBS across 102 sites in Japan. All patients who started teduglutide treatment from August 2021 to August 2022 were enrolled. Safety and effectiveness were evaluated after 6 months of teduglutide treatment and compared with baseline. Results A total of 123 patients aged 2–83 years were included in the safety analysis, including 27 children (aged < 15 years). A total of 51 patients (44 adults, 7 children) reported 117 adverse drug reactions (ADRs). In adults, the most common ADRs were abdominal distension (10.42%), abdominal pain (10.42%), stoma complication (8.33%), and nausea (7.29%). In children, the most common ADR was abdominal pain (11.11%). In the effectiveness analysis, 11.9% (12/101) of patients were able to wean off PS and 42.4% (39/92) were able to achieve at least 20% reduction in their PS volume. The overall mean (standard deviation) change from baseline in the z-score of body weight in children (n = 20) was 0.185 (0.2964). Conclusion In this interim analysis of a 36-month PMS, teduglutide demonstrated an acceptable safety profile and promising effectiveness in patients with SBS. Trial Registration ClinicalTrials.gov identifier, NCT05023382.


  • Open Access

    Portal hypertension in biliary atresia: a Japanese biliary atresia registry study

    by Ryuji Okubo, Masaki Nio, Hideyuki Sasaki, Taichi Fukuzawa, Hironori Kudo, Ryo Ando, Tsuyoshi Sakurai, Masatoshi Hashimoto, Keisuke Tada, Motoshi Wada, et al.

    Purpose: This study aimed to clarify the incidence of portal hypertension (PH) in biliary atresia (BA), its impact on long-term native liver survival rates (NLSRs), and the role of PH treatment. Methods: Data were analyzed from 3,777 patients in the Japanese Biliary Atresia Registry (1989–2021). Incidence and treatment of PH were examined in all patients and in 20-year native liver survivors. A subgroup of 596 jaundice-free native liver survivors was divided into three groups: without PH (A), untreated PH (B), and treated PH (C). Patient characteristics, clinical outcomes, and survival analyses were performed. Results: PH occurred in 46.4% of all patients, with gastroesophageal varices (35.1%) and hypersplenism (36.8%) being most common. Among 759 20-year native liver survivors, 49.8% had PH, largely diagnosed between 2 and 15 years. Group C patients were older at Kasai portoenterostomy and had more cholangitis. Survival analysis showed best outcomes in group A and worst in group C. Conditional native liver survival analysis revealed group B initially had better NLSRs than group C, but differences diminished beyond 15 years. Conclusion: In native liver survivors without jaundice following KP, PH influenced prognosis, but successful treatment enabled long-term survival comparable to patients with mild or no PH.


  • Open Access

    Vitamin K deficiency bleeding and optimal prophylaxis methods in biliary atresia: A surveillance study in Japan

    by Ryuji Okubo, Chiyoe Shirota, Motoshi Wada, Masato Shinkai, Hirofumi Tomita, Satoshi Umeda, Hiromu Miyake, Toshiharu Matsuura, Shigehisa Fumino, Akio Odaka, et al.

    Background: Vitamin K (VK) prophylaxis refers to the administration of VK to newborns to prevent neonatal VK deficiency bleeding (VKDB), which is characterized by intracranial hemorrhage (ICH). This study investigated the relationship between VK prophylaxis methods and VKDB in biliary atresia (BA). Methods: The survey targeted 497 cases in the Japanese Biliary Atresia Registry between 2015 and 2019, of which 395 (79.5%) returned the questionnaire. Of the 395 patients, 289 were selected after excluding cases in which the gestational age was p = 0.018 and p = 0.022, respectively); VKDB was higher in the three‐times method than in the 3‐month method ( p = 0.029). ICH, jaundice disappearance, cholangitis, and native liver survival rates (NLSRs) were not significantly different between groups. When examining the prognosis based on ICH occurrence, the two groups showed no significant differences in jaundice disappearance, cholangitis, and NLSRs. The ICH group had a greater number of cases of delayed mental and/or motor development. Conclusions: In BA, the 3‐month method is effective in preventing VKDB, and early diagnosis is crucial.


  • Usefulness of central venous catheter replacement with a guidewire in patients with intestinal failure: a single-center study

    by Tsuyoshi Sakurai, Masatoshi Hashimoto, Hironori Kudo, Ryuji Okubo, Takuro Kazama, Taichi Fukuzawa, Ryo Ando, Endo Yuki, Keisuke Tada, Motoshi Wada

    Purpose Patients with intestinal failure (IF) require long-term parenteral nutrition using central venous catheters (CVCs), which often require replacement. We adopted a less fallible guidewire replacement (GWR) method and verified its effectiveness and validity. Methods We enrolled 108 cases that underwent a CVC replacement with “GWR” method with IF at our department between 2013 and 2023. We retrospectively reviewed patients’ clinical details with tunneled CVC (Hickman/Broviac catheter). For the analysis, we compared for the same time period the catheter exchange method “Primary placement”; newly inserted catheter by venipuncture. Results The success rate of catheter replacement using GWR was 94.4%. There were six unsuccessful cases. A log-rank test showed no significant difference in catheter survival between primary placement and the GWR, and the time to first infection was significantly longer in the GWR (p = 0.001). Furthermore, no significant differences were observed between the two methods until the first infection, when the exchange indication was limited to infections. In the same way, when the indication was restricted to catheter-related bloodstream infection, there was no significant difference in catheter survival between the two approaches. Conclusion Our GWR procedure was easy to perform and stable, with a high success rate and almost no complications. Moreover, using a guidewire did not increase the frequency of catheter replacement and the infection rate.


  • Open Access

    Utility of the web excision with pre-membranous incision for congenital intestinal atresia-type I and stenosis

    by Hironori Kudo, Takuro Kazama, Taichi Fukuzawa, Ryo Ando, Ryuji Okubo, Tsuyoshi Sakurai, Masatoshi Hashimoto, Yuki Endo, Masaki Nio, Motoshi Wada

    Purpose: This study analyzed the efficacy of web excision combined with a pre-membranous incision on the dilated proximal segment for congenital intestinal atresia with type I and stenosis (CIA-I/S). Patients and methods: Twenty-six patients underwent surgery for CIA-I/S from January 1990 to June 2022. Patients were categorized into 3 groups according to the surgical procedure: Group A, web excision with pre-membranous incision of the dilated intestine (n = 14); Group B, enteroplasty with a trans-membranous vertical incision (n = 7) and Group C, diamond-shaped anastomosis (n = 5). To minimize the impact of obstruction location on outcomes, we specifically examined 17 cases of duodenal atresia/stenosis: Group D-A, (n = 6); Group D-B, (n = 6) and Group D-C, (n = 5). We retrospectively compared the operative and postoperative parameters among the three groups. Results: No patient experienced anastomotic leakage or obstruction. There were no significant differences in operative duration or blood loss among the 3 Groups. The median time to feeding initiation was 4, 6.5, and 5 days in Groups A, B, and C, respectively (p = 0.04) and was 4, 6.5, and 5 days in Groups D-A, D-B, and D-C, respectively (p = 0.04). Conclusion: Web excision, when compared to enteroplasty and diamond-shaped anastomosis, showed comparable results in terms of the operative duration and postoperative complications. However, it may allow for an earlier initiation of enteral nutrition.


  • Risk factors for catheter-related bloodstream infections in patients with intestinal failure undergoing home parenteral nutrition: a single-center study

    by Tsuyoshi Sakurai, Megumi Nakamura, Hideyuki Sasaki, Taichi Fukuzawa, Hironori Kudo, Ryo Ando, Ryuji Okubo, Masatoshi Hashimoto, Kesuke Tada, Motoshi Wada

    Purpose The incidence and risk factors of catheter-related bloodstream infections (CRBSI) in patients with intestinal failure (IF) have not been established, partly because catheter management methods vary from different facilities. This study aimed to identify the risk factors and incidence rate of CRBSIs in patients with IF who were given prophylactic treatment. Methods Sixteen patients with IF who required home parenteral nutrition were enrolled in this study. Prophylactic management of CRBSI included monthly ethanol lock therapy and standardized infection prevention education. The outcomes included the incidence and risk factors of CRBSI. Results The median incidence rate of CRBSI was 1.2 per 1000 catheter days. Univariate analysis showed that the risk of developing CRBSI was significantly associated with short bowel syndrome (< 30 cm) (p = 0.016). Other relevant findings included a significant negative correlation between serum albumin and CRBSI rate (r = − 0.505, p = 0.046), and past history of mixed bacterial infections was significantly associated with increased CRBSI rate (p = 0.013). Conclusion CRBSIs can still develop despite undergoing prophylactic management. Risk factors for CRBSI include the residual intestinal length, nutritional status, and susceptibility to certain microorganisms.


  • Open Access

    Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support

    by Masahiro Chiba, Kouji Masumoto, Tatsuru Kaji, Toshiharu Matsuura, Mayako Morii, Andrew Fagbemi, Susan Dm Hill, Mikko P. Pakarinen, Susan Protheroe, Arun Urs, et al.

    Objectives: Our objective was to evaluate the short‐ and long‐term safety and efficacy of teduglutide treatment in infants and children with short bowel syndrome with intestinal failure (SBS‐IF).Methods: Two open‐label phase 3 studies and 1 extension study investigated the short‐ and long‐term safety and efficacy of teduglutide (0.05 mg/kg/day) in infants and children with SBS‐IF: NCT03571516, 24‐week study of infants who were randomized to receive teduglutide or standard of care (SoC); NCT02980666, 24‐week study of infants and children who all received teduglutide; and NCT03268811, 24‐week extension study of patients who completed NCT02980666 (patients could receive up to 48 weeks of total treatment).Results: Twelve infants and 8 children enrolled in the core studies, and 2 infants and 7 children in the extension study. After 24 weeks of treatment, parenteral support (PS) requirements reduced by ≥20% from baseline for 4 infants (57.1%) and 4 children (66.7%) receiving teduglutide and for 2 infants receiving SoC (50.0%). One infant (50.0%) and 4 children (80.0%) receiving teduglutide maintained the ≥20% reduction in PS at 48 weeks of treatment. Two children receiving teduglutide achieved enteral autonomy, after 12 weeks and 28 weeks of treatment, respectively. All adverse events (AEs) were in line with known impacts of SBS‐IF and adverse reactions to teduglutide. Only one serious AE (abdominal pain) was considered related to teduglutide.Conclusions: Short‐ and long‐term treatment with teduglutide resulted in clinically meaningful reductions in PS requirements for infants and children with SBS‐IF. Teduglutide was well tolerated, and efficacy improved with longer‐term treatment.